Reklama

MILESTONE (MMD): Abstract Acceptance for Presentation at ASRA’s 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting - raport 4

The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced that its abstract entitled “Objective Epidural Space Identification Utilizing Needle-Tip Pressure Measurement is Equivalent to Fluoroscopy/LOR” has been accepted for the American Society of Regional Anesthesia and Pain Medicine’s (ASRA) 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting taking place March 31 through April 2, 2016 in New Orleans.


First author, Dr. Ralf Gephard, MD, has been invited to present the findings of the Company’s prospective, open labeled, clinical trial assessing the CompuFlo® technology during a moderated e-poster session. According to ASRA, only the highest scoring abstracts are selected for moderated sessions. The abstract will be published in the Journal of Regional Anesthesia & Pain Medicine that will coincide with the meeting.

Reklama


Milestone Medical designed the study in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.


The Board of Directors of the Issuer is pleased to announce the acceptance of our abstract in the Journal of Regional Anesthesia & Pain Medicine and looks forward to presenting the findings at the prestigious ASRA 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting


Legal basis: § 3 subparagraph 1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market".

Osoby reprezentujące spółkę:
Joseph D'Agostino - Chief Financial Officer

Reklama

Reklama

Reklama

Reklama

Strona główna INTERIA.PL

Polecamy

Rekomendacje

Finanse / Giełda / Podatki
Bądź na bieżąco!
Odblokuj reklamy i zyskaj nieograniczony dostęp do wszystkich treści w naszym serwisie.
Dzięki wyświetlanym reklamom korzystasz z naszego serwisu całkowicie bezpłatnie, a my możemy spełniać Twoje oczekiwania rozwijając się i poprawiając jakość naszych usług.
Odblokuj biznes.interia.pl lub zobacz instrukcję »
Nie, dziękuję. Wchodzę na Interię »